3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Withdrawn
1
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Conditions
Skin Neoplasms
1
Neoplasm Metastasis
1
Melanoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Esophageal Neoplasms
1
Interventions
Rituximab
24
Cyclophosphamide
20
fludarabine phosphate
16
Mycophenolic Acid
13
Filgrastim
12
Cyclosporine
12
Bortezomib
12
Antilymphocyte Serum
11
Whole-Body Irradiation
10
Peripheral Blood Stem Cell Transplantation
10
Tacrolimus
9
Lenalidomide
9
fludarabine
8
Radiotherapy
7
Methotrexate
7
Cord Blood Stem Cell Transplantation
7
Melphalan
6
Busulfan
6
venetoclax
5
Etoposide
5
tanespimycin
4
ibrutinib
4
Polymerase Chain Reaction
4
Methylprednisolone
4
Granulocyte Colony-Stimulating Factor
4
Flow Cytometry
4
ublituximab
3
thymoglobulin
3
sargramostim
3
carfilzomib
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Lymphoma, Mantle-Cell
×
eprenetapopt
×
Clear all
NCT04419389
2025-03-17
R/R
Aprea Therapeutics
Phase 1/2
Terminated
1 enrolled
4 charts